Table 7 Subsequent therapy for prostate cancer
Percentage of patients (AA group in the present trial) (N = 43) | Percentage of patients (COU-AA-302 trial) (N = 546) | |
|---|---|---|
Patients with subsequent therapy | 14.0%(6 of 43) | 67% (365 of 546) |
AA | 2.3% (1 of 43) | 13%(69 of 546) |
Docetaxel | 2.3% (1 of 43) | 57%(311 of 546) |
Estramustine phosphate | 4.7% (2 of 43) | 0 |
Radium-223 | 7% (3 of 43) | 4%(20 of 546) |